RecruitingPhase 3NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp and Dohme LLC
- Intervention
- Bomedemstat(drug)
- Enrollment
- 400 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2034
Study locations (21)
- University of Michigan ( Site 6000), Ann Arbor, Michigan, United States
- DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina, United States
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus, Ohio, United States
- UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania, United States
- Royal Prince Alfred Hospital ( Site 1003), Camperdown, New South Wales, Australia
- Royal North Shore Hospital ( Site 1001), St Leonards, New South Wales, Australia
- Sunshine Coast Hematology and Oncology Clinic ( Site 1006), Buderim, Queensland, Australia
- Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002), Southport, Queensland, Australia
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000), Adelaide, South Australia, Australia
- Monash Health ( Site 1004), Clayton, Victoria, Australia
- Queen Mary Hospital ( Site 1601), Hksar, Hong Kong
- Azienda Ospedaliera Universitaria Careggi ( Site 2700), Florence, Tuscany, Italy
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703), Alessandria, Italy
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702), Bologna, Italy
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701), Varese, Italy
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06351631 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.